تداخلات أناستروزول
أناستروزول (Arimidex؛ من فئة مثبطات الأروماتاز): 27 تداخلًا موثّقًا في نشرات FDA وصحائف الوقائع التي نفهرسها، وتوزيعها: شديدة 17، متوسطة 0، طفيفة 0، وحالات تفيد فيها نشرة بعدم وجود تداخل مهم 10. كل مُدخل أدناه يقتبس الجملة التي يستند إليها. صفحة الدواء هذه نقطة انطلاق، وليست حكمًا على حالتك.
كيف يبدو أناستروزول
كل النسخ (9)
رسوم مُنشأة من قوائم المنتجات في نشرات FDA: اللون والشكل والحجم والنقش. 9 نسخ موثّقة من 15 شركة مسوّقة.
تداخلات من النشرة
تداخلات شديدة (17)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
• Tamoxifen: Do not use in combination with ARIMIDEX. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (نشرة أناستروزول، التداخلات الدوائية)
لم يُبلَّغ عن تداخل مهم (10)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (نشرة أناستروزول، التداخلات الدوائية)
افحص أناستروزول مع كل ما تتناوله. أضف قائمتك كاملة؛ تُفحص كل الأزواج دفعة واحدة.
افتح في الفاحصليست نصيحة طبية. درجة الشدة تعكس صياغة النشرة، لا ظروفك. فالتنبيه «الشديد» قد يكون أمرًا معتادًا تحت الإشراف، والتنبيه «الطفيف» قد يكون مهمًا عند الجرعات العالية. اسأل صيدليًا.